In-vitro validation of potential modulators of non-alcoholic fatty liver disease (NAFLD)
Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver injury, compromising the liver’s regenerative ability and promoting fibrosis. Despite its widespread impact, therapeutic options remain limited. The only FDA-approved drug for NASH, Rezdiffra, had limited efficacy in pat...
Saved in:
Main Author: | Tang, Daryl Woon Tat |
---|---|
Other Authors: | Torsten Wuestefeld |
Format: | Final Year Project |
Language: | English |
Published: |
Nanyang Technological University
2024
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/181271 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
Similar Items
-
Non-alcoholic fatty liver disease in women – Current knowledge and emerging concepts
by: Eng, PC, et al.
Published: (2023) -
Oxidative stress in NAFLD : role of nutrients and food contaminants
by: Rives, Clémence, et al.
Published: (2021) -
EXPLORING RECEPTOR TYROSINE KINASES IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE
by: BHAVE SAYALI SHRIVARDHAN
Published: (2023) -
Prevalence and clinical associations of posttransplant fatty liver disease
by: Lim, L.G., et al.
Published: (2012) -
Prevalence and clinical associations of posttransplant fatty liver disease
by: Lim, L.G., et al.
Published: (2011)